Huijun Xu
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy.
Journal: Bone marrow transplantation
Published: August 05, 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.
Journal: Nature medicine
Published: April 18, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: April 17, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Bone marrow transplantation
Published: April 12, 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Journal: Journal for immunotherapy of cancer
Published: March 06, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.
Journal: Journal of advanced research
Published: November 16, 2024
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Journal: Experimental hematology & oncology
Published: October 16, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Journal: The New England journal of medicine
Published: April 24, 2024
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma.
Journal: Cell transplantation
Published: September 05, 2023
Last Updated: 09/26/2026